AndroGel Patent Timeline and Generic Availability: What Patients and Clinicians Need to Know

What Is AndroGel and How Does It Work?

AndroGel is a topical hydroalcoholic testosterone gel applied to the skin once daily. Testosterone diffuses through the stratum corneum into the dermis, enters capillary circulation, and restores serum testosterone toward the normal male range of 300 to 1,000 ng/dL. Only about 10% of the applied dose is absorbed systemically, which is why 50 mg of applied testosterone yields roughly 5 mg of absorbed hormone per day.

Mechanism at the Receptor Level

Once in circulation, testosterone binds androgen receptors (AR) in target tissues including skeletal muscle, bone, prostate, and the central nervous system. The testosterone-AR complex translocates to the nucleus, where it acts as a transcription factor regulating genes involved in protein synthesis, erythropoiesis, and libido. A portion of circulating testosterone is also converted to estradiol via aromatase (CYP19A1) and to dihydrotestosterone (DHT) via 5-alpha reductase, both of which contribute to the full hormonal profile of testosterone replacement therapy (FDA prescribing information, AndroGel 1.62%).

Why Topical Delivery Avoids Hepatic First-Pass

Oral testosterone undecanoate aside, oral testosterone forms are avoided in clinical practice because gut and hepatic metabolism destroys most of the dose before it reaches the bloodstream. Transdermal delivery bypasses this entirely. The skin acts as a slow-release reservoir. Testosterone concentrations peak approximately 2 hours after application of AndroGel 1.62% and remain within the normal range for the full 24-hour dosing interval, with a mean C-max of roughly 590 ng/dL and trough values above 300 ng/dL in most treated men (pubmed.ncbi.nlm.nih.gov/26886521/).

Formulation Differences Between 1% and 1.62%

The 1% formulation (AndroGel 1%) requires a 5 g gel packet or pump actuation to deliver 50 mg testosterone. The 1.62% formulation requires only 2.5 g of gel for the same delivered hormone dose, reducing the application volume and potentially improving adherence. Both formulations achieve comparable steady-state serum testosterone levels when dosed appropriately, though the 1.62% product was developed specifically to address the volume complaint common with the original formulation (accessdata.fda.gov).

The T-Trials: What the Best Evidence Actually Shows

The Testosterone Trials (T-Trials) were seven coordinated, double-blind, placebo-controlled RCTs conducted across 12 U.S. Academic medical centers in men aged 65 and older with serum testosterone below 275 ng/dL and at least one symptomatic complaint. Published in the New England Journal of Medicine in 2016, the trials enrolled 788 men total and are the most comprehensive placebo-controlled evaluation of testosterone gel therapy in older hypogonadal men (pubmed.ncbi.nlm.nih.gov/26886521/).

Sexual Function Trial Findings

In the Sexual Function Trial (N=470), men randomized to testosterone gel achieved a mean serum testosterone of 478 ng/dL at 12 months versus 232 ng/dL in the placebo group. The testosterone group reported a statistically significant increase in sexual activity (mean 1.3 more sexual events per month, P<0.001) and sexual desire scores compared with placebo. The trial authors noted: "Testosterone treatment increased sexual activity, sexual desire, and erectile function." (pubmed.ncbi.nlm.nih.gov/26886521/).

Physical Function and Bone Density Findings

The Physical Function Trial found that 12 months of testosterone gel increased 6-minute walk distance by a mean of 13 meters more than placebo (P<0.001). The Bone Trial (N=211) showed that volumetric trabecular bone mineral density at the spine increased by 7.5% in the testosterone group versus 1.0% in placebo (P<0.001) (pubmed.ncbi.nlm.nih.gov/26886521/). These findings support testosterone gel as an effective treatment for musculoskeletal outcomes in older hypogonadal men, though the T-Trials did not have statistical power to detect cardiovascular event differences.

Anemia Sub-Trial

The Anemia Trial enrolled 126 men with unexplained anemia or anemia attributed to low testosterone. Hemoglobin rose by a mean of 1.0 g/dL in testosterone-treated men with unexplained anemia, compared with 0.2 g/dL in placebo (P<0.001). This confirms the erythropoietic effect of testosterone restoration via increased renal erythropoietin production (pubmed.ncbi.nlm.nih.gov/26886521/).

AndroGel's Patent History: A Detailed Timeline

Original 1% Formulation (FDA Approved February 2000)

AbbVie (then Solvay Pharmaceuticals) filed patents on the AndroGel 1% formulation covering the hydroalcoholic gel base composition, specific permeation-enhancing excipients, and the once-daily dosing method. The core composition patents were listed in the FDA Orange Book under NDA 021015. The last of these patents was set to expire around 2020, but multiple generic manufacturers challenged them under Paragraph IV certifications (Hatch-Waxman Act), arguing the patents were invalid or not infringed.

The Paragraph IV Litigation and 2006 Settlement

Between 2003 and 2006, several generic manufacturers including Watson Pharmaceuticals (now Allergan/AbbVie) filed Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications against the AndroGel 1% patents. In 2006, Solvay entered into a settlement agreement with Watson, Paddock, and Par Pharmaceuticals. The Federal Trade Commission later challenged this settlement as an anticompetitive "reverse payment" agreement under antitrust law. The U.S. Supreme Court ruled in FTC v. Actavis (2013) that such agreements could violate antitrust law and must be evaluated under the "rule of reason" standard (ftc.gov). That ruling set a national precedent limiting pay-for-delay settlements across the pharmaceutical industry.

Generic Approval for Testosterone Gel 1% (2014)

Following resolution of the patent disputes, the FDA approved the first generic testosterone gel 1% products in 2014. Manufacturers receiving approval included Upsher-Smith Laboratories and Perrigo Company. These generics are rated AB-equivalent to AndroGel 1%, meaning they are substitutable at the pharmacy counter in most states (accessdata.fda.gov).

The 1.62% Reformulation Strategy

AbbVie filed a separate NDA (NDA 022504) for AndroGel 1.62%, approved May 21, 2011. This new formulation carried its own Orange Book-listed patents on the higher-concentration gel base, the specific pump delivery device, and the titration regimen. The move extended effective market exclusivity on a premium product while generic competition eroded the 1% market share. Generic versions of testosterone gel 1.62% received FDA approval beginning in 2016 from manufacturers including Teva Pharmaceuticals (accessdata.fda.gov).

Current Patent Status (2025)

As of 2025, all major composition-of-matter and method-of-use patents for both AndroGel 1% and 1.62% have expired or been invalidated. The FDA Orange Book lists no blocking patents preventing generic market entry for either strength. Prescribers writing for testosterone gel can expect generic availability at all major U.S. Pharmacies, typically at 70 to 90% lower cost than the brand product.

Generic Testosterone Gel Options: What Prescribers and Patients Should Know

The availability of multiple FDA-approved generic testosterone gels raises practical questions about interchangeability, application site differences, and whether switching mid-therapy affects serum testosterone stability.

AB-Rated Generics and Pharmacy Substitution

FDA's AB rating means the generic has demonstrated bioequivalence to the reference listed drug via pharmacokinetic studies showing a 90% confidence interval for AUC and C-max ratios within 80 to 125% of the brand product. All currently approved generic testosterone gel 1% and 1.62% products carry AB ratings (fda.gov). In 44 states plus Washington D.C., pharmacists may substitute an AB-rated generic without prescriber authorization unless "dispense as written" is specified.

Key Generic Manufacturers (2025)

• Upsher-Smith: testosterone gel 1%, approved 2014
• Teva Pharmaceuticals: testosterone gel 1.62%, approved 2016
• Perrigo Company: testosterone gel 1%, approved 2014
• Amneal Pharmaceuticals: testosterone gel 1%

All four products apply to the shoulders and upper arms. None of the generic gel products are rated for scrotal application; that indication belongs to separate products such as Testim and its generics.

Monitoring After a Brand-to-Generic Switch

Patients switching from AndroGel brand to an AB-rated generic should have serum total testosterone checked 4 weeks after the switch. Though bioequivalence data support equivalent exposure, individual pharmacokinetic variability means 10 to 15% of patients may require dose adjustment after the switch. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends monitoring serum testosterone 3 to 6 months after any therapy change (endocrine.org).

Dosing, Application, and Pharmacokinetics

Starting Dose and Titration Schedule

The standard starting dose of AndroGel 1% is 50 mg testosterone (one 5 g packet or five pump actuations) applied once daily to intact skin of the shoulders, upper arms, or abdomen. The 1.62% formulation starts at 40.5 mg testosterone (2.5 g, two pump actuations) once daily. Dose adjustment is based on serum testosterone measured 2 to 8 weeks after initiation, targeting a mid-normal range of 400 to 700 ng/dL. The maximum approved dose for the 1% formulation is 100 mg/day; for the 1.62% formulation, the maximum is 81 mg/day (accessdata.fda.gov).

Pharmacokinetic Parameters

Steady state is reached by day 2 of consistent daily application. In pharmacokinetic studies supporting the NDA for AndroGel 1.62%, mean steady-state C-max was 590 ng/dL and mean AUC0-24h was approximately 10,000 ng·h/dL at the 40.5 mg starting dose (accessdata.fda.gov). Testosterone from a gel dose is detectable in serum within 30 minutes of application and remains above baseline for the full 24-hour interval in the majority of patients.

Scrotal vs. Non-Scrotal Application Sites

Non-scrotal sites (shoulders, upper arms, abdomen) are specified for all current AndroGel formulations. Scrotal application produces substantially higher DHT levels due to the high 5-alpha reductase activity in scrotal skin, which changes the testosterone-to-DHT ratio and the androgenic profile of therapy. Guidelines from the American Urological Association do not recommend scrotal application for non-scrotal gel formulations (pubmed.ncbi.nlm.nih.gov/30636949/).

Safety Considerations and Contraindications

Transfer Risk

Skin-to-skin transfer of testosterone to female partners or children is the most frequently cited safety concern with topical testosterone. A published pharmacokinetic study showed that testosterone gel transfers to a female partner's skin at approximately 1 to 2% of the applied dose per contact event without a barrier (pubmed.ncbi.nlm.nih.gov/17635950/). The FDA added a black box warning in 2009 requiring AndroGel labeling to state that secondary exposure in women and children may cause virilization. Patients should let the application site dry for 5 to 6 minutes and cover it with clothing before skin contact with others.

Erythrocytosis

Testosterone replacement consistently raises hematocrit. In the T-Trials, testosterone gel raised hematocrit by a mean of 3.0 percentage points versus 0.5 percentage points for placebo (P<0.001) (pubmed.ncbi.nlm.nih.gov/26886521/). The Endocrine Society guideline recommends checking hematocrit at baseline, then at 3 to 6 months, then annually. If hematocrit exceeds 54%, dose reduction or temporary cessation is advised to reduce thromboembolic risk (endocrine.org).

Cardiovascular Signal and the TRAVERSE Trial

The FDA placed a class-wide label warning on testosterone products in 2015 citing a possible increased cardiovascular risk. The TRAVERSE trial (N=5,246, published NEJM 2023) was specifically designed to assess cardiovascular safety of testosterone replacement in men aged 45 to 80 with hypogonadism and elevated cardiovascular risk. TRAVERSE found no statistically significant difference in major adverse cardiovascular events (MACE) between testosterone gel and placebo over a mean follow-up of 33 months (HR 0.96, 95% CI 0.84 to 1.10) (pubmed.ncbi.nlm.nih.gov/37186498/). The FDA reviewed TRAVERSE data and, as of 2024, the label warning remains but the trial provides meaningful reassurance for prescribers treating appropriately selected patients.

Prostate Safety Monitoring

Testosterone therapy is contraindicated in men with known or suspected prostate cancer. Baseline PSA should be measured before starting therapy. The Endocrine Society guideline recommends re-checking PSA at 3 to 6 months and annually thereafter, with urology referral if PSA rises more than 1.4 ng/mL above baseline within any 12-month period (endocrine.org).

Diagnosing Hypogonadism: When Is AndroGel Indicated?

Diagnostic Thresholds

The Endocrine Society defines biochemical hypogonadism as a morning serum total testosterone consistently below 300 ng/dL on two separate measurements, combined with at least one symptom: reduced libido, erectile dysfunction, fatigue, loss of muscle mass, or depressed mood (endocrine.org). Morning blood draw is required because testosterone follows a circadian rhythm with peak levels between 7 a.m. And 10 a.m.

Secondary vs. Primary Hypogonadism

Before initiating AndroGel, clinicians should measure LH and FSH to distinguish primary hypogonadism (testicular failure, elevated LH/FSH) from secondary hypogonadism (pituitary-hypothalamic failure, low or inappropriately normal LH/FSH). Men with secondary hypogonadism who want to preserve fertility are better served by human chorionic gonadotropin (hCG) or clomiphene citrate, as exogenous testosterone suppresses the HPG axis and reduces sperm production. Testosterone gel suppresses LH to near-undetectable levels within 2 to 4 weeks of starting therapy (pubmed.ncbi.nlm.nih.gov/21411847/).

Age-Related Decline vs. Pathologic Hypogonadism

Serum testosterone declines approximately 1 to 2% per year after age 40 in healthy men. This age-related decline is not the same as pathologic hypogonadism. The American College of Physicians' 2020 clinical guidance states: "Clinicians should discuss with patients whether testosterone treatment is appropriate based on their symptoms, values, and clinical circumstances" and does not recommend universal testosterone screening in older men (annals.org). This distinction matters because many men with low-normal testosterone and non-specific symptoms may not benefit from gel therapy, while those with confirmed hypogonadism and specific symptoms clearly do based on the T-Trials data.

Cost Comparison: Brand vs. Generic Testosterone Gel

Without insurance, AndroGel 1.62% brand (30-day supply, 40.5 mg/day starting dose) lists at approximately $500, $600 per month at major U.S. Pharmacies as of 2025. Generic testosterone gel 1.62% from Teva retails for $80, $120 per month for the same dose at the same pharmacies. Generic testosterone gel 1% from Upsher-Smith or Perrigo runs $60, $90 per month for a 50 mg/day dose. GoodRx and similar discount programs can reduce generic costs further to $40, $70 per month depending on location.

The cost differential is driven entirely by the loss of patent exclusivity. No clinical reason favors brand AndroGel over an AB-rated generic for the vast majority of patients. Prescribers who want to allow substitution need only omit the "dispense as written" instruction; those managing a patient who has shown serum testosterone instability on a generic may reasonably request the brand, though insurance prior authorization will typically be required (fda.gov).

Comparing AndroGel to Other Testosterone Delivery Methods

Testosterone Cypionate Injections

Intramuscular testosterone cypionate (100 to 200 mg every 1 to 2 weeks) remains the most commonly prescribed TRT modality in the U.S. Due to low cost (under $30/month generic) and definitive absorption. Its drawback is peak-to-trough variability: serum testosterone may reach 900 to 1,200 ng/dL at 24 to 48 hours post-injection and fall to 300 ng/dL or below before the next dose, a swing that some patients find symptomatic (pubmed.ncbi.nlm.nih.gov/21411847/). Testosterone gels produce a more stable daily profile, which is their main pharmacokinetic advantage over injections.

Testosterone Pellets

Subcutaneous pellets (Testopel) release testosterone over 3 to 6 months and achieve stable serum levels, but insertion requires an office procedure every 3 to 6 months and dose adjustments require a new procedure. Pellets are not AB-rated against any gel formulation and represent a distinct delivery category.

Testosterone Nasal Gel (Natesto)

Natesto (4.5% testosterone nasal gel, 11 mg per actuation, three times daily) received FDA approval in 2014 and is notable for having less suppression of the HPG axis than systemic gels, making it a consideration for men who want to preserve fertility while treating symptoms (accessdata.fda.gov). No generic for Natesto had received FDA approval as of early 2025.